Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SSS59 · 1 trial · 1 indication
Dose limiting toxicity
Safety and tolerability assessed by incidence and severity of adverse events
Determine the maximum tolerated dose and determine the recommended phase II dose
| Arm | Type | Description |
|---|---|---|
| Part A1 | EXPERIMENTAL | Dose escalation will be conducted using accelerated titration and traditional 3+3 design. Dose Escalation Level includes 12 levels, QW IV. Dose extension will be carried out at the selected level. |
| Part A2 | EXPERIMENTAL | Dose escalation will be conducted using a traditional 3+3 design. Dose Escalation Level includes 12 levels, Q2W IV. Dose extension will be carried out at the selected level. |
| Part A3 | EXPERIMENTAL | Dose extension will be carried out at the selected dose level, Q3W, IV. |
| Part B | EXPERIMENTAL | Indication extension will be carried out at the selected level. |
| Name | Type | Description |
|---|---|---|
| SSS59 | DRUG | A humanized antibody targeting MUC17 |
Inclusion Criteria: * Histologically and/or cytologically documented local advanced or recurrent or metastatic malignancies. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. * Expected survival \>3 months. * Signed informed consent form. * Must have adequate organ function. E...
SSS59 is an investigational small molecule being developed for the treatment of malignant tumors. It is currently being studied as a monotherapy in patients with advanced malignant tumors. The drug is in Phase 1 clinical development and has not yet been approved by regulatory authorities.
SSS59 is a small molecule therapeutic being developed for oncology. The specific molecular target of SSS59 has not been disclosed in available information. The drug is being evaluated in a Phase 1 clinical trial for its safety and efficacy in patients with advanced malignant tumors.
SSS59 is being developed by Sunshine Biopharma Inc., a biopharmaceutical company listed on the stock exchange under the ticker symbol SBFM. The company is conducting a Phase 1 clinical trial of SSS59 as a monotherapy for the treatment of advanced malignant tumors.
SSS59 is currently in Phase 1 clinical development. It is an investigational drug and has not received regulatory approval. The ongoing Phase 1 trial is recruiting patients with advanced malignant tumors to evaluate the safety and tolerability of SSS59 as a monotherapy.
SSS59 is being studied in a Phase 1 clinical trial with the identifier NCT06944444. This trial is titled 'A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors' and is currently recruiting participants in China. The trial aims to enroll 154 patients aged 18 years and older.
SSS59 is a distinct investigational drug candidate developed by Sunshine Biopharma Inc. No alternative names for SSS59 have been disclosed in available information. It is being studied as a monotherapy for malignant tumors and is not known to be identical to any other approved or investigational drug.